Charles Schwab’s Crescent Biopharma CBIO Stock Holding History

Charles Schwab’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$905K	Buy	+50,258	New	+$981K	﹤0.01%	3033
2024 Q2	–	Sell	-224	Closed	-$67.1K	–	3650
2024 Q1	$67.1K	Hold	224	–	–	﹤0.01%	3342
2023 Q4	$52.8K	Hold	224	–	–	﹤0.01%	3400
2023 Q3	$33.5K	Hold	224	–	–	﹤0.01%	3450
2023 Q2	$38.9K	Hold	224	–	–	﹤0.01%	3455
2023 Q1	$28.2K	Hold	224	–	–	﹤0.01%	3459
2022 Q4	$67.8K	Buy	+224	New	+$33K	﹤0.01%	3305
2022 Q3	–	Sell	-604	Closed	-$37K	–	3525
2022 Q2	$37K	Buy	+604	New	+$44.7K	﹤0.01%	3434
2022 Q1	–	Sell	-349	Closed	-$51K	–	3598
2021 Q4	$51K	Hold	349	–	–	﹤0.01%	3514
2021 Q3	$77K	Buy	349 +235	+206%	+$49.8K	﹤0.01%	3408
2021 Q2	$27K	Sell	114 -763	-87%	-$194K	﹤0.01%	3408
2021 Q1	$264K	Hold	877	–	–	﹤0.01%	3275
2020 Q4	$330K	Hold	877	–	–	﹤0.01%	3120
2020 Q3	$270K	Sell	877 -5	-0.6%	-$1.91K	﹤0.01%	3064
2020 Q2	$332K	Buy	882 +64	+8%	+$18.1K	﹤0.01%	2996
2020 Q1	$187K	Hold	818	–	–	﹤0.01%	3026
2019 Q4	$433K	Hold	818	–	–	﹤0.01%	2878
2019 Q3	$353K	Hold	818	–	–	﹤0.01%	2926
2019 Q2	$975K	Buy	818 +32	+4%	+$38.3K	﹤0.01%	2584
2019 Q1	$980K	Buy	786 +22	+3%	+$25.2K	﹤0.01%	2558
2018 Q4	$724K	Hold	764	–	–	﹤0.01%	2637
2018 Q3	$1.1M	Buy	764 +24	+3%	+$36.3K	﹤0.01%	2592
2018 Q2	$1.19M	Buy	+740	New	+$1.27M	﹤0.01%	2535
2017 Q2	–	Sell	-196	Closed	-$107K	–	3114
2017 Q1	$107K	Hold	196	–	–	﹤0.01%	3009
2016 Q4	$120K	Hold	196	–	–	﹤0.01%	3031
2016 Q3	$141K	Hold	196	–	–	﹤0.01%	2981
2016 Q2	$143K	Buy	+196	New	+$135K	﹤0.01%	3016

Other funds holding CBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Charles Schwab's CBIO Position: Q2 2026 in Review

Charles Schwab opened a new position in Crescent Biopharma (CBIO) in Q2 2026: 50,258 shares worth $905K. The stake represents ﹤0.01% of the portfolio and ranks #3033 among its holdings. This is a return to the name: Charles Schwab previously reported a position in CBIO as recently as Q1 2024.

Charles Schwab first reported a position in CBIO in Q2 2016 and has held it in 27 quarters since. The position peaked at $1.19M in Q2 2018. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

Charles Schwab held 50,258 shares of Crescent Biopharma worth $905K as of Q2 2026.
Crescent Biopharma was a new Charles Schwab position in Q2 2026.
Crescent Biopharma made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3033 holding.
Charles Schwab first reported a position in Crescent Biopharma in Q2 2016 and has held it in 27 quarters since.
Charles Schwab's Crescent Biopharma position peaked at $1.19M in Q2 2018.
82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.